Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | APVO | Restricted Stock Unit | Award | $0 | +11K | $0.00 | 11K | Jun 7, 2022 | Common Stock | 11K | Direct | F1, F2, F3 |
Id | Content |
---|---|
F1 | As previously disclosed in a Form 4 filed on March 4, 2022, the reporting person was granted 11,000 options on such date. At the time of the grant, there were insufficient shares available for issuance under the Aptevo Therapeutics Inc. 2018 Stock Incentive Plan to make the full grant of equity award to the reporting person that was approved for issuance by Aptevo Therapeutics Inc.'s Compensation Committee. As such, the equity award was split into two separate grants with the first portion of 11,000 options granted on March 4, 2022 and the second portion of 11,000 restricted stock units granted on June 7, 2022, following stockholder approval of an increase in shares available for issuance under the Aptevo Therapeutics Inc. 2018 Stock Incentive Plan (as Amended and Restated). |
F2 | Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. |
F3 | The RSU vests in three approximately equal annual installments beginning on March 3, 2023. |